Curocell's Rimqarto Nears Approval, Marking Milestone in South Korean Biotechnology
On Dec. 10, Curocell's locally developed CAR-T therapy, "Rimqarto," was selected by the Ministry of Health and Welfare as the second drug for expedited approval and market launch through the "Simultaneous Approval-Insurance Evaluation- …